Bolt Biotherapeutics, Inc. Increase (Decrease) in Prepaid Expense and Other Assets
Bolt Biotherapeutics, Inc. (BOLT) reported Increase (Decrease) in Prepaid Expense and Other Assets of $160.00 thousand for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-11.
Financial Statements › Cash Flow › Operating Activities
us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets · last filed 2026-08-11
- Bolt Biotherapeutics, Inc. increase (decrease) in prepaid expense and other assets for the quarter ending 2026-06-30 was $81.00K, a 20.90% increase year-over-year.
- Bolt Biotherapeutics, Inc. increase (decrease) in prepaid expense and other assets for the quarter ending 2026-03-31 was $79.00K, a 53.25% decline year-over-year.
- Bolt Biotherapeutics, Inc. increase (decrease) in prepaid expense and other assets for the quarter ending 2025-12-31 was -$398.00K.
- Bolt Biotherapeutics, Inc. increase (decrease) in prepaid expense and other assets for the quarter ending 2025-09-30 was $86.00K.
- Bolt Biotherapeutics, Inc. increase (decrease) in prepaid expense and other assets for fiscal 2025 was -$76.00K.
- Bolt Biotherapeutics, Inc. increase (decrease) in prepaid expense and other assets for fiscal 2024 was -$2.57M, a 666.30% decline from fiscal 2023.
- Bolt Biotherapeutics, Inc. increase (decrease) in prepaid expense and other assets for fiscal 2023 was $454.00K, a 49.72% decline from fiscal 2022.
- Bolt Biotherapeutics, Inc. increase (decrease) in prepaid expense and other assets for fiscal 2022 was $903.00K, a 58.98% increase from fiscal 2021.
| Period end | Increase (Decrease) in Prepaid Expense and Other Assets 3 month | Increase (Decrease) in Prepaid Expense and Other Assets 6 month | Increase (Decrease) in Prepaid Expense and Other Assets 9 month | Increase (Decrease) in Prepaid Expense and Other Assets 12 month |
|---|---|---|---|---|
| 2026-06-30 | $81.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-11 | $160.00K 10-Q · filed 2026-08-11 | -$238.00K derived: sum of 3 quarters · filed 2026-08-11 | -$152.00K derived: sum of 4 quarters · filed 2026-08-11 |
| 2026-03-31 | $79.00K 10-Q · filed 2026-05-12 | -$319.00K derived: sum of 2 quarters · filed 2026-05-12 | -$233.00K derived: sum of 3 quarters · filed 2026-05-12 | -$166.00K derived: sum of 4 quarters · filed 2026-08-11 |
| 2025-12-31 | -$398.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-12 | -$312.00K derived: sum of 2 quarters · filed 2026-03-12 | -$245.00K derived: sum of 3 quarters · filed 2026-08-11 | -$76.00K 10-K · filed 2026-03-12 |
| 2025-09-30 | $86.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-12 | $153.00K derived: sum of 2 quarters · filed 2026-08-11 | $322.00K 10-Q · filed 2025-11-12 | $247.00K derived: sum of 4 quarters · filed 2026-08-11 |
| 2025-06-30 | $67.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-11 | $236.00K 10-Q · filed 2026-08-11 | $161.00K derived: sum of 3 quarters · filed 2026-08-11 | -$237.00K derived: sum of 4 quarters · filed 2026-08-11 |
| 2025-03-31 | $169.00K 10-Q · filed 2026-05-12 | $94.00K derived: sum of 2 quarters · filed 2026-05-12 | -$304.00K derived: sum of 3 quarters · filed 2026-05-12 | -$2.53M derived: sum of 4 quarters · filed 2026-05-12 |
| 2024-12-31 | -$75.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-12 | -$473.00K derived: sum of 2 quarters · filed 2026-03-12 | -$2.70M derived: sum of 3 quarters · filed 2026-03-12 | -$2.57M 10-K · filed 2026-03-12 |
| 2024-09-30 | -$398.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-12 | -$2.63M derived: sum of 2 quarters · filed 2025-11-12 | -$2.50M 10-Q · filed 2025-11-12 | -$4.24M derived: sum of 4 quarters · filed 2025-11-12 |
| 2024-06-30 | -$2.23M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-14 | -$2.10M 10-Q · filed 2025-08-14 | -$3.84M derived: sum of 3 quarters · filed 2025-08-14 | -$2.57M derived: sum of 4 quarters · filed 2025-08-14 |
| 2024-03-31 | $130.00K 10-Q · filed 2025-05-12 | -$1.61M derived: sum of 2 quarters · filed 2025-05-12 | -$344.00K derived: sum of 3 quarters · filed 2025-05-12 | -$793.00K derived: sum of 4 quarters · filed 2025-05-12 |
| 2023-12-31 | -$1.74M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-24 | -$474.00K derived: sum of 2 quarters · filed 2025-03-24 | -$923.00K derived: sum of 3 quarters · filed 2025-03-24 | $454.00K 10-K · filed 2025-03-24 |
| 2023-09-30 | $1.27M derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-12 | $821.00K derived: sum of 2 quarters · filed 2024-11-12 | $2.20M 10-Q · filed 2024-11-12 | $2.39M derived: sum of 4 quarters · filed 2024-11-12 |
| 2023-06-30 | -$449.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-13 | $928.00K 10-Q · filed 2024-08-13 | $1.12M derived: sum of 3 quarters · filed 2024-08-13 | -$110.00K derived: sum of 4 quarters · filed 2024-08-13 |
| 2023-03-31 | $1.38M 10-Q · filed 2024-05-14 | $1.57M derived: sum of 2 quarters · filed 2024-05-14 | $339.00K derived: sum of 3 quarters · filed 2024-05-14 | $160.00K derived: sum of 4 quarters · filed 2024-05-14 |
| 2022-12-31 | $190.00K derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-21 | -$1.04M derived: sum of 2 quarters · filed 2024-03-21 | -$1.22M derived: sum of 3 quarters · filed 2024-03-21 | $903.00K 10-K · filed 2024-03-21 |
| 2022-09-30 | -$1.23M derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-09 | -$1.41M derived: sum of 2 quarters · filed 2023-11-09 | $713.00K 10-Q · filed 2023-11-09 | -$5.91M derived: sum of 4 quarters · filed 2023-11-09 |
| 2022-06-30 | -$179.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-07 | $1.94M 10-Q · filed 2023-08-07 | -$4.68M derived: sum of 3 quarters · filed 2023-08-07 | $1.88M derived: sum of 4 quarters · filed 2023-08-07 |
| 2022-03-31 | $2.12M 10-Q · filed 2023-05-11 | -$4.50M derived: sum of 2 quarters · filed 2023-05-11 | $2.06M derived: sum of 3 quarters · filed 2023-05-11 | $1.34M derived: sum of 4 quarters · filed 2023-05-11 |
| 2021-12-31 | -$6.62M derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-29 | -$64.00K derived: sum of 2 quarters · filed 2023-03-29 | -$783.00K derived: sum of 3 quarters · filed 2023-03-29 | $568.00K 10-K · filed 2023-03-29 |
| 2021-09-30 | $6.55M derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-10 | $5.84M derived: sum of 2 quarters · filed 2022-11-10 | $7.19M 10-Q · filed 2022-11-10 | $7.52M derived: sum of 4 quarters · filed 2022-11-10 |
| 2021-06-30 | -$719.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-10 | $632.00K 10-Q · filed 2022-08-10 | $966.00K derived: sum of 3 quarters · filed 2022-08-10 | $2.13M derived: sum of 4 quarters · filed 2022-08-10 |
| 2021-03-31 | $1.35M 10-Q · filed 2022-05-12 | $1.69M derived: sum of 2 quarters · filed 2022-05-12 | $2.85M derived: sum of 3 quarters · filed 2022-05-12 | $3.26M derived: sum of 4 quarters · filed 2022-05-12 |
| 2020-12-31 | $334.00K derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-30 | $1.50M derived: sum of 2 quarters · filed 2022-03-30 | $1.91M derived: sum of 3 quarters · filed 2022-03-30 | $1.88M 10-K · filed 2022-03-30 |
| 2020-09-30 | $1.16M derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-09 | $1.58M derived: sum of 2 quarters · filed 2021-11-09 | $1.54M 10-Q · filed 2021-11-09 | |
| 2020-06-30 | $415.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-12 | $382.00K 10-Q · filed 2021-08-12 | ||
| 2020-03-31 | -$33.00K 10-Q · filed 2021-05-13 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Enveric Biosciences, Inc. (ENVB) | United States | $0.007B | -0.63 |
| SYNLOGIC, INC. (SYBX) | United States | $0.007B | |
| Acurx Pharmaceuticals, Inc. (ACXP) | United States | $0.007B | -0.97 |
| CNS Pharmaceuticals, Inc. (CNSP) | United States | $0.007B | |
| Apimeds Pharmaceuticals US, Inc. (APUS) | United States | $0.008B | |
| Ernexa Therapeutics Inc. (ERNA) | United States | $0.006B | |
| InMed Pharmaceuticals Inc. (INM) | $0.008B | -0.65 | |
| Pulmatrix, Inc. (PULM) | United States | $0.006B | |
| Ensysce Biosciences, Inc. (ENSC) | United States | $0.008B | -0.37 |
| EXICURE, INC. (XCUR) | United States | $0.008B | -1.54 |